Talk:Rosiglitazone

From Wikipedia, the free encyclopedia

Jump to: navigation, search

This is the talk page for discussing improvements to the Rosiglitazone article.
This is not a forum for general discussion of the article's subject. Put new text under old text. Click here to start a new topic. Please sign and date your posts by typing four tildes (`~~~~`). New to Wikipedia? Welcome! Ask questions, get answers.	Be polite, and welcoming to new users Assume good faith Avoid personal attacks For disputes, seek dispute resolution	Article policies No original research Neutral point of view Verifiability

WikiProject Pharmacology

(Rated C-class, High-importance)

Pharmacy and Pharmacology portal

This article is within the scope of WikiProject Pharmacology, a collaborative effort to improve the coverage of Pharmacology on Wikipedia. If you would like to participate, please visit the project page, where you can join the discussion and see a list of open tasks.

C

This article has been rated as C-Class on the project's quality scale.

High

This article has been rated as High-importance on the project's importance scale.

WikiProject Medicine

(Rated C-class, Mid-importance)

Medicine portal

This article is within the scope of WikiProject Medicine, which recommends that this article follows the Manual of Style for medicine-related articles and use high-quality medical sources. Please visit the project page for details or ask questions at Wikipedia talk:WikiProject Medicine.

C

This article has been rated as C-Class on the project's quality scale.

Mid

This article has been rated as Mid-importance on the project's importance scale.

[edit] Initial comments

It might be worthwhile to critique the Nissen study here for its questionable methodology, as well as include more recent study information re increased CV risk. Also, might be worth to mention of Rosiglitazone's effect of LDL metabolism (see Thiazolidinediones review by Hannele Yki-Järvineni, 2004; figure 4). --Xris0 (talk) 18:33, 13 March 2008 (UTC)

The statement in WIKI that "In February 2010, David Graham, the FDA's associate director of drug safety, recommended that rosiglitazone be taken off the market." is wholly inaccurate. David Graham, the reviewer of the FDA's office of surveillance and epidemiology estimated in a memo dated October 2008, 2008 mind you, stated it should be taken off the market".(First word) Graham has publicly been criticized by the FDA in the past for his opinions.(WIKI)----DM 08:28, 20 June 2006 —Preceding unsigned comment added by 202.80.63.2 (talk • contribs) [Bangalore, India]

[edit] Not sure whether it's worth mentioning

A generic version of this drug is available outside of the US. It is manufactured by Cipla Ltd. (India) and is called Senzia. InsultComicDog (talk) 00:54, 4 May 2010 (UTC)

[edit] July 9, 2010 article

Caleb Hellerman (July 9, 2010). "Key diabetes drug study was flawed, review charges". CNN. http://www.cnn.com/2010/HEALTH/07/09/avandia.diabetes.research.fda/?hpt=T1.

-- John Broughton (♫♫) 01:26, 10 July 2010 (UTC)

And here from the NYT:

http://www.nytimes.com/2010/07/10/health/10diabetes.html?src=me&ref=health Gandydancer (talk) 11:13, 11 July 2010 (UTC)

[edit] Nissen/Wolski

They've done an updated meta-analysis. OR was 1.3 for MI but no change in cardiovascular death - http://archinte.ama-assn.org/cgi/content/abstract/170/14/1191. Probably citable after the recent raft of additions. JFW | T@lk 10:39, 27 July 2010 (UTC)

Talk:Rosiglitazone

Contents

[edit] Initial comments

[edit] Not sure whether it's worth mentioning

[edit] July 9, 2010 article

[edit] Nissen/Wolski

Personal tools

Namespaces

Variants

Views

Actions

Search

Navigation

Interaction

Toolbox

Print/export